HC Wainwright & Co. Maintains Buy on Purple Biotech, Raises Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Purple Biotech (NASDAQ:PPBT) and raises the price target from $7 to $9.
August 31, 2023 | 8:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Purple Biotech and raises the price target from $7 to $9.
The raised price target by HC Wainwright & Co. indicates a positive outlook for Purple Biotech. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100